About the Editors
Dae-Myung Jue PhD is a Professor in the Department of Biochemistry, Catholic University of Korea, Seoul. His research interests are proteins and enzymes involved in inflammatory diseases, and the development of strategies to control their expression. Dr. Jue graduated from Seoul National University and KAIST and received his PhD degree from the Catholic University of Korea in 1981. From 1987 to 1989, he was a postdoctoral Fogarty Fellow with Dr. A. Cerami at the Rockefeller University in New York. Since 1981, he has been working in the Department of Biochemistry, Catholic University of Korea. Dr. Jue was an Associate Editor of Korean Journal of Biochemistry from 1991 to 1995, and since then has continued his editorial work with Experimental & Molecular Medicine. He was the President of the Korean Society of Medical Biochemistry and Molecular Biology in 2008 and is a member of the National Academy of Medicine of Korea.
Sung-Yup Cho MD, PhD is an Associate Professor at the Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Korea. He obtained M.D. from Seoul National University College of Medicine, and his Ph.D. in biochemistry from Seoul National University College of Medicine. During the Ph.D. course, he studied the regulation of the mTOR signaling and apoptosis pathways by calcium-dependent enzyme transglutaminase 2. After that, he worked as a post-doctoral researcher and research professor at Ewha Womans University in Korea, where he investigated the biological meanings of genomic alterations in cancers and pursued novel targeted cancer treatment strategies. From 2016 to 2018, he worked as a Clinical Assistant Professor at Ewha Womans University Mokdong Hospital in Korea. In 2018, he moved to his current position at the Seoul National University. He mainly focuses on understanding the molecular mechanism of cancer drug responsiveness based on genomic profiles and functional genomic analyses using genome-wide screening system.
Kyung-Chul Choi, PhD is an Associate Professor at the Department of Biomedical Sciences and Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Korea. He received his BS degree and MS degree at Korea University, and received Ph.D. degree in Department of Biochemistry and Molecular Biology at Yonsei University College of Medicine in 2010. He developed his carrier when he worked as a postdoctoral training at the Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine. Currently, he is Associate Professor in the University of Ulsan College of Medicine, Asan Medical Center (AMC) in Korea from 2016. His main focus of research is the epigenetic regulation of cancer development and metastasis, and the discovery of novel epigenetic inhibitors for therapy of cancer cells and cancer stem cells. Also his research has focused on the molecular mechanism of epigenetic regulators in cancer and inflammation.
Kyungho Choi MD, PhD is a molecular immunologist and an Associate Professor at the Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Korea. He received his MD from Seoul National University College of Medicine in 1994 and his PhD from the Department of Biochemistry and Molecular Biology of the same college in 1998. He developed his career as an immunologist when he worked as a postdoctoral fellow in Dr. Ron Schwartz's laboratory (Laboratory of Cellular and Molecular Immunology) at NIH, USA from 2001 to 2005. After moving back to Korea in 2005, he joined the Research Institute National Cancer Center as a Senior Scientist. In 2012, he moved to his current position at the Seoul National University. His current research focuses on molecular mechanism of T cell tolerance and its application to cancer immunotherapy and treatment of autoimmune diseases.
Dr. Yeun-Jun Chung is a Professor of Medical Microbiology, Catholic University Medical College, Korea. He is also a director of Precision Medicine Research Center and Integrated Research Center for Genome Polymorphism in the same university. After graduating the Catholic University Medical College (MD), he studied immunogenetics and oncogenomics for his MS and PhD. Then, he moved to Dr. Allan Bradley’s Lab in Wellcome Trust Sanger Institute (Cambridge, UK) to study chromosome engineering and genome analysis. After back to Korea, he has studied genomics based personalized medicine for past twenty years. Since he founded Integrated Research Center for Genome Polymorphism in 2007, he has studied Variomics and Oncogenomics using NGS, array-CGH, GWAS, MLPA-CE-SSCP and BI tools. Recently, he founded Precision Medicine Research Center to support cancer precision medicine in the clinical filed in addition to the pure
Hyonchol Jang PhD is a Senior Scientist at the Research Institute, National Cancer Center, Korea. He majored in Chemistry at Seoul National University, After mandatory military service, he changed his major to Molecular and Cellular Biology and received his PhD degree from the same University in 2006, He developed his carrier when he worked as a Postdoctoral Associate/Fellow at the Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine from 2006 to 2013. He revealed a novel epigenetic pathway to regulate p53 function in cancer cells, and also revealed a direct link between nutritional condition and embryonic stem cell pluripotency. In 2013, he joined the Research Institute, National Cancer Center as a Senior Scientist. His current research interest is stem cell epigenetic and cancer.
Dr. Jae-woo Kim is a Professor of the Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Korea. He also works as a Director of Systemic Medicine Research Center in the same university. He received his MD and PhD degree from Yonsei University College of Medicine with a study of glucose metabolism in liver. When he worked as a Postdoctoral Researcher in Johns Hopkins University, School of Medicine, his research interest was expanded into adipose tissue biology and fat metabolism. His major field of research are focused on the mechanisms of adipogenesis, hepatic steatosis, steroid-induced metabolic complications, as well as on finding new therapeutic targets or developing new concept of treatment for such diseases. For those, his study encompasses glucose and fat metabolism in liver, muscle, adipose tissue, and intestine, as well as comparative systemic medicine including cancer metabolic pathways.
Jong Il Kim
Jong-Il Kim got his MD and PhD degree from Seoul National University College of Medicine. After postdoctoral training in the Rockefeller University and Beth Israel Deaconess Hospital, hehas been servingas a professor in the Department of Biochemistry and Molecular Biology in Seoul National University. His major interest is the identification of genome variations related with human diseases. He and his colleagues have recently published several papers revealing genomic variations in Asian population using next-generation sequencing technology. He is now actively investigating the relationship of Asian-specific genomic variations and the rare and common diseases such as cancers and metabolic disorders frompatients and large cohorts in Mongolia and Korea.
Yoon-Keun Kim, MD, PhD is a physician scientist. He received his MD from Seoul National University in 1987 and received his PhD in 1997. From 2002 to 2003, he was a visiting Assistant Professor at the Division of Pulmonary and Critical Care at Yale University, USA. After moving his position to the Department of Life Science at the Pohang University of Science and Technology (POSTECH), Korea, he has extended his interests to the pathophysiology of immune-based inflammatory diseases and translational research covering cutaneous, gastrointestinal, and cardiovascular diseases in addition to the respiratory diseases. In addition, he is a leader of convergence of industry, academy, and research as well as convergence of basic and clinical research. In 2014, he took the position as Principal of Ewha Institute of Convergence Medicine and Professor of Ewha Womans University Medical Center. He will lead the future of convergence of diverse fields of research and industry.
Dr. Kook, MD, PhD, holds his degrees from Chonnam National University Medical School in Gwangju, where he currently serves as Professor of Pharmacology. After finishing his doctoral course, he worked in the internal medicine at Kyoto University Hospital (mentor: Dr. Hiroshi Itoh) and in the cardiovascular research institute at University of Pennsylvania (mentor: Dr. Jonathan A. Epstein) as a visiting scholar. He currently administers government-sported research grants such as the National Research Laboratory (Epigenetic Regulation of Cardiac and Skeletal Muscle Diseases Laboratory) and the Basic Research Laboratory (Cardiac Remodeling Research Center). With the use of genetically engineered animals, human heart and muscle samples, and primary cultured vascular smooth muscle cells/cardiomyocyte models, his laboratory aims to discover pathophysiologic mechanisms and therapeutic targets in heart and skeletal muscle diseases. These works focus on roles of epigenetic regulators and their non-histone targets in cardiac hypertrophy/heart failure, polyubiquitination-mediated vascular calcification, non-coding RNA-mediated regulation of vascular diseases, and posttranslational modification of key transcription factors in the skeletal muscle differentiation and regeneration.
Mi-Na Kweon, Ph.D., obtained her doctoral degree in Department of Nutrition, School of Medicine at University of Tokushima (Japan). Then, she completed her education with a post-doctoral appointment at Department of Oral Biology at University of Alabama at Birmingham (USA). Then, she served as Assistant Professor in the Department of Mucosal Immunology, at the Research Institute for Microbial Diseases, at Osaka University (Japan) and then moved as Chief in the Mucosal Immunology Section of International Vaccine Institute (Korea). Since 2014, she is Associate Professor in the University of Ulsan College of Medicine / Asan Medical Center (Korea). Her interesting field is (1) to develop animal model for preclinical study of vaccine and drug efficacy, (2) to clarify underlying mechanism for mucosal immunity following infection and inflammation and (3) to identify a role of commensal microbiomes on the regulation of inflammation in the mucosal tissues and metabolic diseases. She has published over 100 papers in peer-reviewed journals and is an expert both on basic aspects of mucosal immunology and approaches for novel mucosal vaccine development.
Dr. Lee received the undergraduate training at Seoul National University and the graduate training at POSTECH. He then moved to NIH, Bethesda, MD, and later to Harvard Medical School, Boston, MA for postdoctoral studies in neurodegenerative diseases. Dr. Lee started his research group at the Parkinson's Institute in Sunnyvale, CA in 2000, where he developed a research program for the study of pathophysiology of alpha-synuclein. He then moved to Konkuk University in Seoul, Korea in 2006, where he continued his work on alpha-synuclein and performed a series of studies on alpha-synuclein secretion and its roles in aggregate propagation and neuroinflammation. In 2015, Dr. Lee moved to Seoul National University in Seoul, Korea. While he continues the work on alpha-synuclein and Lewy body diseases, Dr. Lee is currently expanding the spectrum of his research program that now includes other neurodegenerative diseases-linked proteins, such tau and TDP-43.
Do Sik Min
Do Sik Min Ph.D., is an associate professor in the Department of Molecular Biology, Pusan National University, Korea. He majored in Biotechnology inYonseiUniversity and received Ph.D. degree in biochemistry from Pohang University of Science and Technology (POSTECH) in 1996. He developed his carrier when he worked as a postdoctoral fellow in the Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicinefrom 1996 to 1998. His research has focused on the functional mechanism of molecules bridging between cancer and inflammation, along with autophagy, cancer metabolism and tumor microenvironment.
Dr. Oh is director for Center for Next Generation for Stem Cell Based Cell Therapeutics, nominated by Korean FDA and director for Catholic High Performance Cell Therapy Center, in Catholic University of Korea, College of Medicine, Seoul. He served as President of Korean Society of Stem Cell Research (KSSCR) and currently serving as CEO in the board meeting of KSSCR. He also serves as advisory member for Presidential Committee for National Bioethics, Korea. He graduated Catholic Medical School, Seoul, Korea, earned Ph.D in Temple University, USA, worked as National Research Fellow for Canadian Society for Cancer Research. His main focus of research is the regulation of hematopoietic stem cells and mesenchymal stromal cells in the light of tissue regeneration. He also serves as an International Committee Member for International Society for Stem Cell Research (ISSCR).